WO2000014271A1 - METHOD FOR STUDYING PROTEIN INTERACTIONS $i(IN VIVO) - Google Patents
METHOD FOR STUDYING PROTEIN INTERACTIONS $i(IN VIVO) Download PDFInfo
- Publication number
- WO2000014271A1 WO2000014271A1 PCT/US1999/020207 US9920207W WO0014271A1 WO 2000014271 A1 WO2000014271 A1 WO 2000014271A1 US 9920207 W US9920207 W US 9920207W WO 0014271 A1 WO0014271 A1 WO 0014271A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- complexed
- acceptor fluorophore
- cell
- luciferase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the method could be used with a wide variety of proteins and in a wide variety of living cells. Also preferably, the method could be used to determine the interactions between molecules other than proteins.
- a method for determining whether a first protein interacts with a second protein within a living cell comprises providing the first protein complexed to a donor luciferase and the second protein complexed to an acceptor fluorophore within the cell.
- the donor luciferase is capable of luminescence resonance energy transfer to the acceptor fluorophore when the first protein is in proximity to the second protein.
- the complexed first protein and the complexed second protein are allowed to come into proximity to each other within the cell.
- any fluorescence from the acceptor fluorophore is detected. Fluorescence of the acceptor fluorophore resulting from luminescence resonance energy transfer from the donor luciferase to acceptor fluorophore the indicates that the first protein has interacted with the second protein.
- providing the first protein complexed to a donor luciferase and the second protein complexed to an acceptor fluorophore comprises genetically engineering DNA and transferring the genetically engineered DNA to the living cell causing the cell to produce the first protein complexed to a donor luciferase and the second protein complexed to an acceptor fluorophore.
- the cell which is provided with the first protein complexed to a donor luciferase and the cell which is provided with the second protein complexed to an acceptor fluorophore are mammalian cells.
- the donor luciferase provided is Renilla luciferase.
- the acceptor fluorophore provided is an Aequorea green fluorescent protein.
- the detection of acceptor fluorophore fluorescence is performed using spectrofluorometery.
- the present invention includes a method for determining whether a first protein interacts with a second protein in a living cell using luminescent resonance energy transfer (LRET).
- LRET luminescent resonance energy transfer results from the transfer of excited state energy from a donor luciferase to an acceptor fluorophore.
- LRET luminescent resonance energy transfer
- the efficiency of luminescence resonance energy transfer is dependent on the distance separating the donor luciferase and the acceptor fluorophore, among other variables. Generally, significant energy transfers occur only where the donor luciferase and acceptor fluorophore are less than about 80 A of each other.
- the present invention utilizes luminescence resonance energy transfer to determine whether an interaction takes place between a first protein and a second protein in a living cell. This is accomplished by complexing a first protein to the donor luciferase and complexing the second protein to the acceptor fluorophore and placing the complexed first protein and the complexed second protein in the cell under conditions suitable for an interaction between the first protein and the second protein to take place. If the first protein interacts with the second protein, the donor luciferase will come close enough to the acceptor fluorophore for luminescence resonance energy transfer to take place and the acceptor fluorophore will fluoresce.
- this method allows for the detection of interaction between the first protein and the second protein even though the interaction cannot be detected by optical methods such as conventional microscopy.
- the specific labeling of the proteins in living cells can be achieved through genetic engineering methods where the introduction of fluorescent dyes into living cells is very difficult. Further, fluorescent dyes photobleach quickly while light emission of a luciferase such as Renilla luciferase originates from an enzymatic reaction that is relatively stable if substrate and oxygen are supplemented.
- complexing a first protein to the donor luciferase refers to joining the donor luciferase to the first protein in a manner that the donor luciferase and the first protein stay in essentially the same proximity to one another during interaction between the first protein and the second protein.
- complexing a second protein to the acceptor fluorophore refers to joining the acceptor fluorophore to the second protein in a manner that the acceptor fluorophore and the second protein stay in essentially the same proximity to one another during interaction between the first protein and the second protein.
- Such complexing can be done, for example, by genetically engineering the cell to produce a fusion protein containing the donor luciferase and first protein, and the acceptor fluorophore and the second protein.
- the present invention uses Renilla luciferase as the donor luciferase and "humanized" Aequorea green fluorescent protein ('humanized' GFP) as the acceptor fluorophore.
- Renilla luciferase is a 34 kDa enzyme purified from Renilla reniformis. The enzyme catalyzes the oxidative decarboxylation of coelenterazine in the presence of oxygen to produce blue light with an emission wavelength maximum of 471 nm.
- Renilla luciferase was used as the donor luciferase because it requires an exogenous substrate rather than exogenous light for excitation. This, advantageously, eliminates background noise from an exogenous light source and from autofluorescence, and allows easy and accurate quantitative determination of light production.
- 'Humanized' GFP is a 27 kDa protein fluorophore that has an excitation maximum at 480 nm. It has a single amino acid difference from wild-type Aequorea green fluorescent protein. 'Humanized' GFP was chosen as the acceptor fluorophore because its excitation spectrum overlaps with the emission spectra of Renilla luciferase. Additionally, emissions from 'humanized' GFP can be visualized in living cells. Further, 'humanized'
- GFP is expressed well in the mammalian cells transfected with 'humanized' GFP cDNA that were used to demonstrate this method.
- IGFBP 6 insulin-like growth factor binding protein 6
- IGF- II insulin-like growth factor II
- the Renilla luciferase cDNA was fused to IGFBP 6 cDNA and 'humanized' GFP cDNA was fused to IGF-II cDNA.
- Living cells were transfected with the fused cDNAs and the fusion proteins were expressed. Cell extracts were produced and mixed.
- the substrate for the Renilla luciferase moiety of the fused Renilla luciferase-IGFPB 6 protein was added. Finally, fluorescence from the 'humanized' GFP moiety of the fused 'humanized' GFP-IGF-II protein was detected. Demonstration one method according to the present invention will now be described in greater detail.
- IGFBP-6 cDNA SEQ ID NO: l, GenBank accession number M69054, encoded IGFBP-6, SEQ ID NO:2, which was used as the first protein.
- Renilla luciferase cDNA SEQ ID NO:3, GenBank accession number M63501, encoded Renilla luciferase, SEQ ID NO:4, which was used as the donor luciferase.
- Insulin cDNA SEQ ID NO:9, accession number AH002844, encoded insulin, SEQ ID NO: 10.
- Insulin, fused to 'humanized' GFP was used as a control protein because insulin is homologous to IGF-II, but it does not bind to IGFBP-6.
- the cDNA of prepro-IGF-II carried on an EcoRI fragment was cloned into pBluescript KS (+) II vector.
- the insert was sequenced using T7 and T3 primers and confirmed to contain the known cDNA sequence of prepro-IGF-II.
- the 5' end of the IGF-II precursor was connected to the T7 promoter in the pBluescript KS (+) II vector.
- An IGF-II 3' primer was designed to generate a Notice of Allowance restriction site, to remove the D and E domains of prepro-IGF-II, and to maintain the Notice of Allowance fragment of the 'humanized' GFP in frame with the open reading frame of IGF-II.
- the IGF-II fragment was amplified with PCR using the T7 promoter primer and the IGF-II 3' primer.
- the PCR-amplified IGF-II fragment was digested by EcoRI and Not I and cloned into pCDNA3.1 (+) vector (Invitrogen, Carlsbad, CA, US) producing pCDNA-IGF-II.
- the Notice of Allowance fragment of the 'humanized' GFP was inserted into the Not I site of pCDNA-IGF-II producing pC-IGF-II-GFP.
- the cDNA for precursor of insulin which contained a signal peptide the B, C and A domains, was modified in a manner corresponding to the IGF-II fragment, above.
- the 'humanized' GFP cDNA was then linked to the 3' end of the modified insulin cDNA to produce pC-INS-GFP.
- IGFBP 6 cDNA was amplified by PCR from a plasmid named
- Rat-tagged human IGFBP6 Rat-tagged human IGFBP6.
- the stop codon of IGFBP 6 was removed and the open reading frame of IGFBP 6 was in frame with Renilla luciferase cDNA from pCEP4-RUC (Mayerhofer R, Langridge WHR, Cormier MG and Szalay AA. Expression of recombinant Renilla luciferase in trans genie plants results in high levels of light emission. The Plant Journal 1995 ;7; 1031-8).
- the linking of the Renilla luciferase cDNA to the 3' end of modified IGFBP 6 cDNA produced pC-IGFBP 6-RUC.
- COS-7 cells African green monkey kidney cell, American Type Culture Collection CRL 1651
- DMEM Dulbecco's Modified Eagle Medium
- streptomycin 100 mg/ml antibiotic antimycotic solution containing a final concentration of penicillin 100 unit/ml, streptomycin 100 mg/ml and amphotericin B 250 ng/ml (Sigma-Aldrich Co., St. Louis, MO, US) in 5% CO 2 .
- Groups of 1x10° of these cells were plated the day before transfection and were approximately 50% to 60% confluent at the time of transfection. Forty mg of each plasmid fusion DNA were precipitated and resuspended into
- fusion proteins IGF-II-GFP and IGFBP 6-RUC having the expected molecular weights of about 36 kDa and 56 kDa, respectively, were detected using immunoblot analysis. This confirmed the presence of both fusion proteins in the transiently transfected cells.
- cell extracts from these transiently transfected cells were used to carry out a protein binding assay based on energy transfer between the Renilla luciferase and 'humanized' GFP moieties of the fusion proteins.
- the COS cells were washed twice with PBS and harvested using a cell scraper in luciferase assay buffer containing 0.5 M NaCl, 1 mM EDTA and 0.1 M potassium phosphate at a pH 7.5.
- the harvested cells were sonicated 3 times for 10 seconds with an interval of 10 seconds using a Fisher Model 550 Sonic Dismembrator (Fisher Scientific, Pittsburgh, PA, US) to produce cell extracts.
- the cell extracts containing IGF-II-GFP and IGFBP 6-RUC were mixed and 0.1 ⁇ g of coelenterazine was immediately added.
- Spectrofluorometry was performed using a SPEX FluoroMax ® (Instruments S.A., Inc., Edison, NJ). The spectrum showed a single emission peak at 471 nm, which corresponds to the known emission of Renilla luciferase.
- the spectrofluorometry of the cell extracts was carried out at a longer time, but the spectral pattern did not change over time.
- Control cell extract mixtures from cells transfected with pC-INS-GFP and pC-IGFBP 6-RUC were made similarly and their spectra traced.
- the traces showed only one peak at 471 nm, which corresponds to the emission peak of Renilla luciferase.
- the spectral pattern did not change over time.
- protein-protein interactions were also detected by the detection of LRET using corresponding methods in E. coli cells and mammalian cells which were co-transformed.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU58056/99A AU752675B2 (en) | 1998-09-03 | 1999-09-02 | Method for studying protein interactions (in vivo) |
CA002341314A CA2341314A1 (en) | 1998-09-03 | 1999-09-02 | Method for studying protein interactions in vivo |
EP99945460A EP1109931A4 (en) | 1998-09-03 | 1999-09-02 | METHOD FOR STUDYING PROTEIN INTERACTIONS $i(IN VIVO) |
JP2000569011A JP2002524087A (en) | 1998-09-03 | 1999-09-02 | How to study protein interactions in vivo |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9906898P | 1998-09-03 | 1998-09-03 | |
US60/099,068 | 1998-09-03 | ||
US13583599P | 1999-05-24 | 1999-05-24 | |
US60/135,835 | 1999-05-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000014271A1 true WO2000014271A1 (en) | 2000-03-16 |
Family
ID=26795497
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/020207 WO2000014271A1 (en) | 1998-09-03 | 1999-09-02 | METHOD FOR STUDYING PROTEIN INTERACTIONS $i(IN VIVO) |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1109931A4 (en) |
JP (1) | JP2002524087A (en) |
CN (1) | CN1160470C (en) |
AU (1) | AU752675B2 (en) |
CA (1) | CA2341314A1 (en) |
WO (1) | WO2000014271A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1533619A2 (en) | 2003-11-20 | 2005-05-25 | F. Hoffmann-La Roche Ag | Specific markers for metabolic syndrome |
US7771952B2 (en) | 2002-06-26 | 2010-08-10 | Abott Laboratories | Modulators and modulation of the interaction between RGM and Neogenin |
WO2011083147A1 (en) | 2010-01-08 | 2011-07-14 | Cemm-Forschungsinstitut Für Molekulare Medizin Gmbh | Wave1 inhibition in the medical intervention of inflammatory diseases and/or infections caused by a pathogen |
WO2011131626A1 (en) | 2010-04-19 | 2011-10-27 | Medizinische Universität Innsbruck | Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity |
US8647887B2 (en) | 2009-01-29 | 2014-02-11 | Commonwealth Scientific And Industrial Research Organisation | Measuring G protein coupled receptor activation |
US8906864B2 (en) | 2005-09-30 | 2014-12-09 | AbbVie Deutschland GmbH & Co. KG | Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
US9102722B2 (en) | 2012-01-27 | 2015-08-11 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration |
US9175075B2 (en) | 2009-12-08 | 2015-11-03 | AbbVie Deutschland GmbH & Co. KG | Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein |
US10415960B2 (en) | 2015-04-06 | 2019-09-17 | Worldvu Satellites Limited | Elevation angle estimating system and method for user terminal placement |
US11579149B2 (en) | 2017-11-01 | 2023-02-14 | Queen's University At Kingston | Hippo pathway bioluminescent biosensor |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1920021B (en) * | 2005-08-24 | 2010-05-05 | 中国医学科学院基础医学研究所 | Preparation method of activated insulin-like growth factor-II mediated by insulin-like growth factor binding protein-6 |
CN101620233B (en) * | 2009-05-27 | 2012-10-31 | 华中科技大学 | Method for detecting interaction of proteins |
CN102798717B (en) * | 2012-06-15 | 2014-11-26 | 杭州师范大学 | Method for detecting activity of O6-methylguanine-DNA (Deoxyribose Necleic Acid) methyltransferase |
CN103616502B (en) * | 2013-09-12 | 2016-05-25 | 西北农林科技大学 | Based on the method for bacterial luciferase BRET technology for detection protein interaction |
CN110794129B (en) * | 2018-08-01 | 2020-12-01 | 清华大学 | Method for detecting interaction between biological molecules and regulating factor thereof in cell and used reagent |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4318707A (en) * | 1978-11-24 | 1982-03-09 | Syva Company | Macromolecular fluorescent quencher particle in specific receptor assays |
US4604364A (en) * | 1974-01-04 | 1986-08-05 | Kosak Kenneth M | Bioluminescent tracer composition and method of use in immunoassays |
US5418155A (en) * | 1989-12-29 | 1995-05-23 | University Of Georgia Research Foundation, Inc. | Isolated Renilla luciferase and method of use thereof |
US5491084A (en) * | 1993-09-10 | 1996-02-13 | The Trustees Of Columbia University In The City Of New York | Uses of green-fluorescent protein |
US5683888A (en) * | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
US5811238A (en) * | 1994-02-17 | 1998-09-22 | Affymax Technologies N.V. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US5866348A (en) * | 1993-02-10 | 1999-02-02 | Parkard Instrument Company, Inc. | Bioluminescence measurement system |
US5891646A (en) * | 1997-06-05 | 1999-04-06 | Duke University | Methods of assaying receptor activity and constructs useful in such methods |
US5976796A (en) * | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES8607563A1 (en) * | 1983-10-13 | 1986-06-01 | Univ Georgia Res Found | Bioluminescent immunoassays. |
WO1999066324A2 (en) * | 1998-06-16 | 1999-12-23 | Biosignal Packard Inc. | A bioluminescence resonance energy transfer (bret) system and its use |
-
1999
- 1999-09-02 JP JP2000569011A patent/JP2002524087A/en active Pending
- 1999-09-02 WO PCT/US1999/020207 patent/WO2000014271A1/en not_active Application Discontinuation
- 1999-09-02 CA CA002341314A patent/CA2341314A1/en not_active Abandoned
- 1999-09-02 CN CNB99811958XA patent/CN1160470C/en not_active Expired - Fee Related
- 1999-09-02 AU AU58056/99A patent/AU752675B2/en not_active Ceased
- 1999-09-02 EP EP99945460A patent/EP1109931A4/en not_active Withdrawn
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4604364A (en) * | 1974-01-04 | 1986-08-05 | Kosak Kenneth M | Bioluminescent tracer composition and method of use in immunoassays |
US4318707A (en) * | 1978-11-24 | 1982-03-09 | Syva Company | Macromolecular fluorescent quencher particle in specific receptor assays |
US5683888A (en) * | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
US5418155A (en) * | 1989-12-29 | 1995-05-23 | University Of Georgia Research Foundation, Inc. | Isolated Renilla luciferase and method of use thereof |
US5866348A (en) * | 1993-02-10 | 1999-02-02 | Parkard Instrument Company, Inc. | Bioluminescence measurement system |
US5491084A (en) * | 1993-09-10 | 1996-02-13 | The Trustees Of Columbia University In The City Of New York | Uses of green-fluorescent protein |
US5811238A (en) * | 1994-02-17 | 1998-09-22 | Affymax Technologies N.V. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US5976796A (en) * | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
US5891646A (en) * | 1997-06-05 | 1999-04-06 | Duke University | Methods of assaying receptor activity and constructs useful in such methods |
Non-Patent Citations (1)
Title |
---|
See also references of EP1109931A4 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7771952B2 (en) | 2002-06-26 | 2010-08-10 | Abott Laboratories | Modulators and modulation of the interaction between RGM and Neogenin |
EP2053409A1 (en) | 2003-11-20 | 2009-04-29 | F. Hoffmann-La Roche Ag | Specific markers for metabolic syndrome |
EP1533619A2 (en) | 2003-11-20 | 2005-05-25 | F. Hoffmann-La Roche Ag | Specific markers for metabolic syndrome |
US8906864B2 (en) | 2005-09-30 | 2014-12-09 | AbbVie Deutschland GmbH & Co. KG | Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
US9605069B2 (en) | 2008-02-29 | 2017-03-28 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM a protein and uses thereof |
US8647887B2 (en) | 2009-01-29 | 2014-02-11 | Commonwealth Scientific And Industrial Research Organisation | Measuring G protein coupled receptor activation |
US9175075B2 (en) | 2009-12-08 | 2015-11-03 | AbbVie Deutschland GmbH & Co. KG | Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein |
WO2011083147A1 (en) | 2010-01-08 | 2011-07-14 | Cemm-Forschungsinstitut Für Molekulare Medizin Gmbh | Wave1 inhibition in the medical intervention of inflammatory diseases and/or infections caused by a pathogen |
WO2011131626A1 (en) | 2010-04-19 | 2011-10-27 | Medizinische Universität Innsbruck | Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity |
US9102722B2 (en) | 2012-01-27 | 2015-08-11 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration |
US9365643B2 (en) | 2012-01-27 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Antibodies that bind to repulsive guidance molecule A (RGMA) |
US10106602B2 (en) | 2012-01-27 | 2018-10-23 | AbbVie Deutschland GmbH & Co. KG | Isolated monoclonal anti-repulsive guidance molecule A antibodies and uses thereof |
US10415960B2 (en) | 2015-04-06 | 2019-09-17 | Worldvu Satellites Limited | Elevation angle estimating system and method for user terminal placement |
US11579149B2 (en) | 2017-11-01 | 2023-02-14 | Queen's University At Kingston | Hippo pathway bioluminescent biosensor |
Also Published As
Publication number | Publication date |
---|---|
EP1109931A4 (en) | 2004-12-15 |
CA2341314A1 (en) | 2000-03-16 |
CN1160470C (en) | 2004-08-04 |
JP2002524087A (en) | 2002-08-06 |
AU752675B2 (en) | 2002-09-26 |
CN1323353A (en) | 2001-11-21 |
AU5805699A (en) | 2000-03-27 |
EP1109931A1 (en) | 2001-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1109931A1 (en) | METHOD FOR STUDYING PROTEIN INTERACTIONS $i(IN VIVO) | |
JP4459058B2 (en) | Photoprotein with improved bioluminescence | |
WO2019174633A1 (en) | Fluorescent probe for branched chain amino acids and use thereof | |
US20140329718A1 (en) | Nicotinamide Adenine Dinucleotide Gene Encoding Fluorescent Probe, Preparation Method Therefor and Application Thereof | |
CN113603756B (en) | Corynebacterium glutamicum membrane protein Ncgl2775, surface display system and construction method thereof | |
JP2007508841A5 (en) | ||
Wang et al. | A study of protein-protein interactions in living cells using luminescence resonance energy transfer (LRET) from Renilla luciferase to Aequorea GFP | |
US8552151B2 (en) | Mutant blue fluorescent protein and method of using the same for fluorescence energy transfer and blue fluorescent fish | |
CN111269324B (en) | Fusion protein of Gauss luciferase and digoxin single-chain antibody and application thereof | |
CN113801211B (en) | Corynebacterium glutamicum protein Ncgl0717, surface display system and construction method thereof | |
AU2012227790B2 (en) | Probe for analyzing biological tissue and method for utilizing same | |
JP2011211983A (en) | Protein molecule pair, gene encoding protein molecule pair, and cell producing gene transfer vector and protein molecule pair | |
JP6051438B2 (en) | Calcium sensor protein using red fluorescent protein | |
EP1840213A1 (en) | Target physiological function inactivator using photosensitizer-labeled fluorescent protein | |
CN104277120B (en) | NAD gene code fluorescence probe and its preparation method and application | |
CN116068198B (en) | PPI in-situ detection method and carrier, diagnostic reagent, kit and application thereof | |
KR20200137596A (en) | Composition for diagnosis acute kidney transplant rejection reaction and diagnostic kit containing the same | |
CN102181465B (en) | Fluorescent clone screening vector and preparation and application thereof | |
KR102210877B1 (en) | Flavin mononucleotide binding protein variants derived from Arabidopsis thaliana with enhanced fluorescence intensity | |
WO2021253126A1 (en) | Cleavable linkers for protein translation reporting | |
CN117551208A (en) | L-2-hydroxyglutarate biosensor based on cyclic rearrangement fluorescent protein and application thereof | |
WO2024056560A1 (en) | Novel phagocytosis assay combining a synthetic cell death switch and a phagocytosis reporter system | |
ES2445018B1 (en) | VARIANTS OF THE CALCIUM SENSITIVE FUSION PROTEIN tdTOMATO-AEQUORINA | |
JP2005287327A (en) | Method for synthesis of new protein labeled with site-specific fluorescence | |
NZ614600B2 (en) | Probe for analyzing biological tissue and method for utilizing same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99811958.X Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09786377 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2000 569011 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 58056/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999945460 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999945460 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
ENP | Entry into the national phase |
Ref document number: 2341314 Country of ref document: CA Ref document number: 2341314 Country of ref document: CA Kind code of ref document: A |
|
WWG | Wipo information: grant in national office |
Ref document number: 58056/99 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999945460 Country of ref document: EP |